Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leo Kager

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
The Journal of Clinical Investigation|July 15, 2025
The NUDIX hydrolase NUDT5 influences purine nucleotide metabolism and thiopurine pharmacologyLeo Kager, Kaan Boztug
Leukemia Research|July 3, 2010
Old drug--new insights--better treatment?Christopher Diakos, Leo Kager
Cureus|October 7, 2024
Helmut Gadner: A Charismatic Leader, Visionary, and Pioneer in Pediatric OncologyMilen Minkov, Leo Kager
Current Opinion in Hematology|June 7, 2006
Pharmacogenomics of acute lymphoblastic leukemiaLeo Kager, William E Evans
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|October 16, 2024
Pharmacogenomics in Pediatric Oncology Research and TreatmentLeo Kager, William E Evans
Expert Review of Clinical Pharmacology|January 16, 2014
Antileukemic drug effects in childhood acute lymphoblastic leukemiaNicolas Pottier, Meyling Cheok, Leo Kager
Future Oncology (London, England)|September 22, 2016
Novel insights and therapeutic interventions for pediatric osteosarcomaLeo Kager, Gevorg Tamamyan, Stefan Bielack
Therapeutics and Clinical Risk Management|July 3, 2010
Review of mifamurtide in the treatment of patients with osteosarcomaLeo Kager, Ulrike Pötschger, Stefan Bielack
Expert Opinion on Drug Metabolism & Toxicology|April 18, 2015
Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?Leo Kager, Christopher Diakos, Stefan Bielack
Japanese Journal of Clinical Oncology|November 17, 2009
Synchronous and metachronous lung metastases in high-grade osteosarcomaLeo Kager, Beate Kempf-Bielack, Stefan Bielack
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
The Journal of Clinical Investigation|July 15, 2025
The NUDIX hydrolase NUDT5 influences purine nucleotide metabolism and thiopurine pharmacologyLeo Kager, Kaan Boztug
Leukemia Research|July 3, 2010
Old drug--new insights--better treatment?Christopher Diakos, Leo Kager
Cureus|October 7, 2024
Helmut Gadner: A Charismatic Leader, Visionary, and Pioneer in Pediatric OncologyMilen Minkov, Leo Kager
Current Opinion in Hematology|June 7, 2006
Pharmacogenomics of acute lymphoblastic leukemiaLeo Kager, William E Evans
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|October 16, 2024
Pharmacogenomics in Pediatric Oncology Research and TreatmentLeo Kager, William E Evans
Expert Review of Clinical Pharmacology|January 16, 2014
Antileukemic drug effects in childhood acute lymphoblastic leukemiaNicolas Pottier, Meyling Cheok, Leo Kager
Future Oncology (London, England)|September 22, 2016
Novel insights and therapeutic interventions for pediatric osteosarcomaLeo Kager, Gevorg Tamamyan, Stefan Bielack
Therapeutics and Clinical Risk Management|July 3, 2010
Review of mifamurtide in the treatment of patients with osteosarcomaLeo Kager, Ulrike Pötschger, Stefan Bielack
Expert Opinion on Drug Metabolism & Toxicology|April 18, 2015
Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?Leo Kager, Christopher Diakos, Stefan Bielack
Japanese Journal of Clinical Oncology|November 17, 2009
Synchronous and metachronous lung metastases in high-grade osteosarcomaLeo Kager, Beate Kempf-Bielack, Stefan Bielack
Pageof 11